newsfilter
← Latest News
Business Wire·

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

Following closing, the combined company will advance Crescent's portfolio of precision-engineered biologics to improve outcomes for patients with solid tumors Crescent's lead program CR-001, a tetravalent PD-1 x VEGF